Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Clinical trial NCT06568172 · SUSPENDED

Trial details

NCT number: NCT06568172
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 3
Study type: INTERVENTIONAL

Eyelid Squamous Cell Carcinoma Recurrent Eyelid Squamous Cell Carcinoma Recurrent Skin Acantholytic Squamous Cell Carcinoma Recurrent Skin Clear Cell Squamous Cell Carcinoma Recurrent Skin Lymphoepithelial Carcinoma Recurrent Skin Spindle Cell Squamous Cell Carcinoma Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation Resectable Eyelid Squamous Cell Carcinoma Resectable Skin Acantholytic Squamous Cell Carcinoma Resectable Skin Clear Cell Squamous Cell Carcinoma Resectable Skin Lymphoepithelial Carcinoma Resectable Skin Spindle Cell Squamous Cell Carcinoma

Start date: 2025-02-18
Primary completion: 2031-08-14
Enrollment: 420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.